Age Related Macular Degeneration Clinical Trial
Official title:
The Evaluation of Nutrition Status in Persons With Age-Related Macular Degeneration
Verified date | October 2017 |
Source | Hacettepe University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Including eye health, nutrition plays a vital role for the sustainability of individuals
health life. There is an increasing global concern about the issues related with eye health.
In 2010, in order to take attention to these issues, World Health Organization (WHO) defined
the main reasons of vision disorders as refraction defects of eye diseases (43 %), cataract
(33 %), glaucoma (2 %), age-related macular degeneration (AMD) (1 %), diabetic retinopathy (1
%) and undetermined natural reasons (18 %). This report also stated the three biggest reasons
of blindness as cataract (51 %), glaucoma (8 %) and AMD (5 %).
AMD is a multi-factorial disease in which the genetic predisposition plays important role
with environmental factors and metabolic conditions, except for age. Especially cigarette is
the secondary important risk factor for dry-type AMD. In the Age Related Eye Disease Study
(AREDS), it was stated that AMD prevalence is higher in white races, compared with races
which are not white. At the same time, AREDS searched the effect of diet supplements on the
progression of AMD disease. In terms of the patients followed for six years, it was reported
that the formulation C and E vitamins, beta carotene and zinc decreased the progression risk
of AMD from middle levels to advanced levels by 34 %. In AREDS-2 study completed in 2012, it
was shown that the extraction of beta carotene from the formulation and the decrease of zinc
did not affect the progression rate of the disease. In the group using beta carotene,
including persons who were used to smoke but gave up at least one year ago, the rate of
becoming lung cancer was observed as substantially high. Moreover, the use of lutein and
zeaxanthin instead of beta carotene in the formula did not increase the risk of lung cancer.
In addition, it was shown that omega-3 fatty acids did not decrease risk progression.
In current data, the effect of the intake of carotenoid and antioxidant increased with diet
on AMD is not coherent. Likewise, the epidemiological evidences about the relation between
diet fat intake and AMD are contradictory. The consumption of fatty fish is related with
increased poly-unsaturated fatty acid intake and decreases the risk of AMD. However, it was
reported the high rate of total fat intake in other studies as risk factor for AMD. In
another study, there was not any important relation found between diet fat intake and AMD
occurrence after the correction of other variables. In the interventional AREDS-2 study, it
was reported that the additional intake of long-chain omega-3 poly-unsaturated fatty acids
did not have any beneficial effect.
The pathophysiological mechanism responsible from the possible relation between obesity and
AMD is not clearly known. There are various hypotheses about how obesity causes AMD. In the
first hypothesis, obesity can cause AMD after obesity increases systematic oxidative stress.
In the second hypothesis, obesity can play a role in AMD pathophysiology as the cause of
hyperleptinemia. The studies also prescribed that inflammation could play a role in the
progression of AMD and also showed that plasma fibrinogen and other inflammation indicators
could be related with late AMD. In Pathologies Oculaires Liées à l'Age (POLA) study made with
the participation of many Europeans, it was observed that the progression of late AMD
increased by two times in obese individuals and in early AMD, obesity did not affect the
progression of disease. In the treatment of this disease which have age-related progression,
proper nutrition, vitamin/mineral/supplement usage and the development of precautionary
strategies play an important role.
When compared with Body Mass Index (BMI), it was found that the measure of abdominal obesity
(waist/hip rate and waist circumference) was the better determinant of chronic diseases such
as diabetics and cardiovascular disease. Some evidences in the United States of America
indicated that the relation between waist/hip rate and AMD gave stronger results when
compared with the relation between BMI and AMD. For middle age cohort, after six years of
follow-up, a group of researchers reported that the decrease of waist/hip rate also decreased
the risk of AMD and the results were the same for waist circumference, even if the evidences
were weak. In another study, it was reported that the increase of waist/hip rate or waist
circumference also increased the progression of AMD.
This study was planned with the aim of determining the occurrence of AMD by evaluating
dietary total antioxidant capacity, diet components and some anthropometric measures of
individuals having age related macular degeneration (AMD). In the study, the possible effect
of nutrition on the occurrence of disease was evaluated by comparing healthy individuals with
dietary total antioxidant capacity and some anthropometric measures of individuals with AMD.
Status | Completed |
Enrollment | 200 |
Est. completion date | February 20, 2016 |
Est. primary completion date | October 1, 2015 |
Accepts healthy volunteers | |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Subject older than 50 years old - Clinical diagnosis of Age-Related Macular Degeneration Disease (Both Dry and Wet type) Exclusion Criteria: - Subject complying with a special diet - History of cardiovascular disease - History of eye surgery - Subject younger than 50 years old |
Country | Name | City | State |
---|---|---|---|
Turkey | Hacettepe University Hospital Department of Ophthalmology Polyclinic | Ankara | Altindag |
Lead Sponsor | Collaborator |
---|---|
Hacettepe University |
Turkey,
Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol. 2004 Jun;122(6):883-92. — View Citation
Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmo — View Citation
Defay R, Delcourt C, Ranvier M, Lacroux A, Papoz L. Relationships between physical activity, obesity and diabetes mellitus in a French elderly population: the POLA study. Pathologies Oculaires lieés á l' Age. Int J Obes Relat Metab Disord. 2001 Apr;25(4): — View Citation
Klein BE, Klein R, Lee KE, Jensen SC. Measures of obesity and age-related eye diseases. Ophthalmic Epidemiol. 2001 Sep;8(4):251-62. — View Citation
Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol. 2001 Sep;119(9):1259-65. — View Citation
Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003 Jun;121(6):785-92. — View Citation
Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001 Apr;108(4):697-704. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body Mass Index (BMI) | It will calculate by researcher with BMI formula: kg/m^2 | up to 20 weeks | |
Primary | Dietary total antioxidant capacity of participants | 3 day food record of participants will be taken and evaluated by researcher. Nutrition information System (BeBIS) software will be used for calculate daily consumption of nutrients. | up to 20 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |